Lead Sponsor

Hannover Medical School

Age

0 - 21 years

Sex

ALL

Healthy Volunteers

No

•Aged between 0-21 years
•Patients suffering from either refractory de novo AML or relapsed AML or patients with very high risk AML in CR1
•In sexually active patients two reliable contraception methods are used. This includes every combination of a hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring) or of an intrauterine device(IUD) with a barrier method (e.g. diaphragm, cervical cap, or condom) or with a spermicide.
•Written informed consent of patient, parents or legal guardians

•Severe renal impairment (GFR \< 30% predicted for age)
•Pregnant or lactating females
•Current participation in another clinical trial
•Patients ≥ 12 years old for Group 1 ("BuCyMel") (patients younger that 12 years continue to be included)

Related studies

NCT07500441 · Acute Myeloid Leukemia (AML)

NCT05756777 · Acute Myeloid Leukemia (AML)

NCT05768932 · Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, and more

NCT07451912 · Acute Myeloid Leukemia (AML), CEBPA Mutation, and more

NCT06660368 · Relapsed or Refractory Acute Myeloid Leukemia (AML)

Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML